The frequent comorbidity of anxiety and depression, particularly among elderly, is widely recognized by clinicians, but the debate continues as to whether the combined diagnostic designation is merited. This article reviews the debate over the mixed diagnosis, discusses treatment implications, and reviews a small treatment study undertaken with elderly patients. Ten community-dwelling, older adults diagnosed with generalized anxiety disorder and subsyndromal depression (n = 6) or generalized anxiety disorder and major depressive disorder (n = 4) were started on a 12-week, open-label trial of nefazodone. Clinicians’ ratings on the Clinical Global Impression of Change and patients’ self-ratings of symptoms on the Beck Depression Inventory and the Beck Anxiety Inventory identified statistically significant gains in patients’ overall pre/post functioning. Nefazodone was efficacious in symptom alleviation in patients with comorbid anxiety and depression. Further double-blind, randomized investigations with newer antidepressant medications are required to extend these preliminary findings with nefazodone.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed.Washington, DC: American Psychiatric Association; 1980.
2.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, DC: American Psychiatric Association; 1994.
3.
Barlow DH, Campbell LA. Mixed anxiety-depression and its implications for models of mood and anxiety disorders. Compr Psychiatry. 2000;41:55-60.
4.
Schoevers RA, Beekman ATF, Deeg DJH, Jonker C, van Tilburg W. Comorbidity and risk-patterns of depression, generalized anxiety disorder and mixed anxiety-depression in later life: results from the AMSTEL study. Int J Geriatr Psychiatry. 2003;18:994-1001.
5.
Silverstone PH, von Studnitz E. Defining anxious depression: going beyond comorbidity. Can J Psychiatry. 2003;48:675-680.
6.
Tyrer P.The case for cothymia: mixed anxiety and depression as a single diagnosis. Br J Psychiatry. 2001;179:191-193.
7.
Barkow K, Heun R, Wittchen H, Ustun TB, Gansicke M, Maier W.Mixed anxiety-depression in a 1 year follow-up study: shift to other diagnoses or remission?J Affect Disord. 2004;79:235-239.
8.
Wittchen H, Schuster P, Live R.Comorbidity and mixed anxiety-depressive disorder: clinical curiosity or pathophysiological need?Hum Psychopharmacol Clin Exp. 2001;16:S21-S30.
9.
Kessler R, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R Major Depressive Disorder in the general population: results from the US national comorbidity survey. Br J Psychol. 1996;168:17-30.
10.
Wittchen H, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the national comorbidity survey. Arch Gen Psychol. 1994;51:355-364.
11.
Brown C, Schulberg, HC, Madonia MJ, Shear MK, Houck PR. Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders. Am J Psychol. 1996;153:1293-1300.
12.
Sartorius N, Ustun TB, Lecrubier Y, Wittchen H.Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychol. 1996;168:38-43.
13.
Beekman A, de Beurs E, van Balkom A, Deeg D, van Dyck R, van Tilburg W. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychol. 2000;157:89-95.
14.
Lenze E, Mulsant BH, Shear MK, et al.Comorbid anxiety disorders in depressed elderly patients. Am J Psychol. 200;157:722-728.
15.
Casten RJ, Parmelee PA, Kleban MH, Lawton MP, Katz IR. The relationships among anxiety, depression, and pain in a geriatric institutionalized sample. Pain. 1995;61:271-276.
16.
Smith SL, Colenda CC, Espeland MA. Factors determining the level of anxiety state in geriatric primary care patients in a community dwelling. Psychosomatics. 1994;35:50-58.
17.
Stahl SM. Mixed anxiety and depression: clinical implications. J Clin Psychol. 1993;54(suppl):33-38.
18.
Liebowitz MR. Mixed anxiety and depression: should it be included in DSM-IV?J Clin Psychol. 1993;54(suppl):4-7; discussion 17-20.
19.
Coryell W, Endicott J, Winokur G.Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. Am J Psychol. 1992;149:100-107.
20.
Schatzberg AF. Fluoxetine in the treatment of comorbid anxiety and depression. J Clin Psychol Monographs. 1995;13:2-12.
21.
Flint AJ, Rifat SL. Two-year outcome of elderly patients with anxious depression. Psychol Res. 1997;66:23-31.
22.
Fawcett J.Targeting treatment in patients with mixed symptoms of anxiety and depression. J Clin Psychol. 1990;51:40-43.
23.
Lecrubier Y.The burden of depression and anxiety in general medicine. J Clin Psychiatry. 2001;62:4-9.
24.
Hurst M, Lamb HM. Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs. 2000;14:51-80.
25.
Montgomery SA, Judge R.Treatment of depression with associated anxiety: comparisons of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr Scand Suppl. 2000;403:9-16.
26.
Rausch JL, Hobby HM, Shendarkar N, Johnson ME, Li J.Fluvoxamine treatment of mixed anxiety and depression: evidence for serotonergically mediated anxiolysis. J Clin Psychopharmacol. 2001;21:139-142.
27.
Spalletta G, Pasini A, Caltagirone C.Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. J Clin Psychopharmacol. 2002;22:263-266.
28.
Rudolph RL, Entsuah R, Chitra R.A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol. 1998;18:136-144.
29.
Klerman GL. Depression and panic anxiety: the effect of depressive co-morbidity on response to drug treatment of patients with panic disorder and agoraphobia. J Psychol Res. 1990;24:27-41.
30.
Rickels K, Schweizer E.The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychol. 1993;54:20-23.
Spina E, Scordo M.Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging. 2002;19:299-320.
33.
Fawcett J, Marcus RN, Anton SF, O’Brien K, Schwiderski U.Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychol. 1995;56:37-42.
34.
Zajecka JM, Ross JS. Management of comorbid anxiety and depression. J Clin Psychol. 1995;56:10-13.
35.
Lesperance F, Frasure-Smith N, Laliberte M, et al.An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Can J Psychiatry. 2003;48:695-701.
36.
Keller MB. Efficacy of nefazodone in chronic depression. J Clin Psychol. 2002;63:24-27.
37.
Beck AT, Ruch AJ, Shaw BF, Emery G.Cognitive Therapy of Depression. New York: Guilford; 1979.
38.
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897.
39.
Beck AT, Weissman A, Lester D, Trexler P.The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol. 1974;42:861-865.
40.
Guy W.ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: U.S. Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
